167 related articles for article (PubMed ID: 31582907)
21. Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients.
Tang C; Zhu L; Zhang L; Tan C; Peng Z; Liu B; Liu W; Hu H; Bai Y; Wang B; Lin L; Liang J; Li X; Guo Y; Liu Y
Clin Chim Acta; 2020 Nov; 510():88-96. PubMed ID: 32645388
[TBL] [Abstract][Full Text] [Related]
22. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
23. A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis.
Choi W; Cho Y; Park SY; Hwang KH; Han JY; Lee Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):213-222. PubMed ID: 32705364
[TBL] [Abstract][Full Text] [Related]
24. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.
Xiang Z; Wan R; Zou B; Qi X; Huang Q; Kumar S; Pitman JL; Zhou G; Song Q
Anal Bioanal Chem; 2018 Oct; 410(26):6751-6759. PubMed ID: 30128808
[TBL] [Abstract][Full Text] [Related]
25. Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.
Zhang Y; Xu Y; Zhong W; Zhao J; Chen M; Zhang L; Li L; Wang M
Oncotarget; 2017 Jan; 8(4):5861-5873. PubMed ID: 28052016
[TBL] [Abstract][Full Text] [Related]
26. Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.
Szpechcinski A; Bryl M; Wojcik P; Czyzewicz G; Wojda E; Rudzinski P; Duk K; Moes-Sosnowska J; Maszkowska-Kopij K; Langfort R; Barinow-Wojewodzki A; Chorostowska-Wynimko J
Adv Med Sci; 2021 Sep; 66(2):336-342. PubMed ID: 34274564
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
28. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
[TBL] [Abstract][Full Text] [Related]
29. Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan.
Ho HL; Huang CC; Ku WH; Ho CL; Lin CH; Yu SL; Chou TY
J Chin Med Assoc; 2019 Jun; 82(6):473-476. PubMed ID: 30932938
[TBL] [Abstract][Full Text] [Related]
30. Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.
Zhang L; Coffin J; Formenti K; Chu Q; Izevbaye I
BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35091437
[TBL] [Abstract][Full Text] [Related]
31. Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients.
Liu HE; Vuppalapaty M; Wilkerson C; Renier C; Chiu M; Lemaire C; Che J; Matsumoto M; Carroll J; Crouse S; Hanft VR; Jeffrey SS; Di Carlo D; Garon EB; Goldman J; Sollier E
Front Oncol; 2020; 10():572895. PubMed ID: 33117705
[TBL] [Abstract][Full Text] [Related]
32. Five Technologies for Detecting the
Chen YL; Lin CC; Yang SC; Chen WL; Chen JR; Hou YH; Lu CC; Chow NH; Su WC; Ho CL
Front Oncol; 2019; 9():631. PubMed ID: 31380273
[TBL] [Abstract][Full Text] [Related]
33. A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for
Shin JY; Kim JO; Lee MR; Kim SR; Beck KS; Kang JH
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33266057
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients.
Li Y; Xu Y; Wu X; He C; Liu Q; Wang F
J Thorac Dis; 2019 Jul; 11(7):3004-3014. PubMed ID: 31463130
[TBL] [Abstract][Full Text] [Related]
35. T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer.
Li JY; Ho JC; Wong KH
Oncotarget; 2018 Jun; 9(46):27929-27939. PubMed ID: 29963252
[TBL] [Abstract][Full Text] [Related]
36. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Wang W; Song Z; Zhang Y
Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
[TBL] [Abstract][Full Text] [Related]
37. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
38. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
[TBL] [Abstract][Full Text] [Related]
39. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
[TBL] [Abstract][Full Text] [Related]
40. Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants.
Asaka S; Yoshizawa A; Saito K; Kobayashi Y; Yamamoto H; Negishi T; Nakata R; Matsuda K; Yamaguchi A; Honda T
Int J Oncol; 2018 Jun; 52(6):2110-2118. PubMed ID: 29620164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
